Grant: Discovery Grants Program - Group
Université de Montréal
$47,000.00
Central sensitization in osteoarthritis pain: Validation of rodent models, development of biomarkers for diagnosis and anti-inflammatory inhibitors for treatment.
FY 2017-18
Summary
Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain and disability in older adults. We hypothesized that innate immune system activation, best documented in response to pathogens, likely plays a role in the induction of inflammatory mediators and the specific cellular infiltrates seen in OA. We previously linked immune system activation to the processes of sensitization, thought to be the basis for arthritic pain that appears spontaneously (that is, at rest), and hyperalgesia (increased pain responses to noxious stimulation) and allodynia (pain in response to normally non-painful stimulation). We demonstrated this in both experimental rat and dog, as well as natural cat and dog, OA models. Sensitization also facilitates the efferent neuronal processes through which the nervous system influences the inflammatory/immune process. This could contribute to the frequently observed disparity between clinical pain severity and the extent of joint changes in subjects with OA. Such observations have prompted work to investigate the mechanisms of central pain perception in OA. By studying chronic pain syndromes in different species, we have validated a method of central sensitization assessment that includes specific neuroproteome quantification, neuromechanical testing, neurophysiological sensitization testing (mechanical temporal summation) and functional neuroimaging. We will apply these to the determination of the experimental rat OA model best suited to studying sensitization, before confirming the role of inflammatory/immune signalling pathways using genetically modified mouse models. Finally, to study the central role of pro-inflammatory cytokines in OA structure and pain pathogenesis, we will block interleukin-1 receptor binding using various pharmacological approaches. Our hypothesis is that the inhibition produced by an original negative allosteric modulator will have the greatest effects on joint alterations and neuronal sensitization, along with the fewest side effects. This will open the field for an innovative anti-inflammatory pharmacological approach to early OA.
Program
Discovery Grants Program - Group
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
441651-2013
Name nom
Troncy, Eric
Department département
Biomédecine vétérinaire
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2013
Award amount
47000
Program id
RGPGP
Program name en
Discovery Grants Program - Group
Program name fr
Programme de subventions à la découverte - équipe
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Partie
5
Nb partie
5
Application title
Central sensitization in osteoarthritis pain: Validation of rodent models, development of biomarkers for diagnosis and anti-inflammatory inhibitors for treatment.
Keyword
NSERC
Application summary
Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain and disability in older adults. We hypothesized that innate immune system activation, best documented in response to pathogens, likely plays a role in the induction of inflammatory mediators and the specific cellular infiltrates seen in OA. We previously linked immune system activation to the processes of sensitization, thought to be the basis for arthritic pain that appears spontaneously (that is, at rest), and hyperalgesia (increased pain responses to noxious stimulation) and allodynia (pain in response to normally non-painful stimulation). We demonstrated this in both experimental rat and dog, as well as natural cat and dog, OA models. Sensitization also facilitates the efferent neuronal processes through which the nervous system influences the inflammatory/immune process. This could contribute to the frequently observed disparity between clinical pain severity and the extent of joint changes in subjects with OA. Such observations have prompted work to investigate the mechanisms of central pain perception in OA. By studying chronic pain syndromes in different species, we have validated a method of central sensitization assessment that includes specific neuroproteome quantification, neuromechanical testing, neurophysiological sensitization testing (mechanical temporal summation) and functional neuroimaging. We will apply these to the determination of the experimental rat OA model best suited to studying sensitization, before confirming the role of inflammatory/immune signalling pathways using genetically modified mouse models. Finally, to study the central role of pro-inflammatory cytokines in OA structure and pain pathogenesis, we will block interleukin-1 receptor binding using various pharmacological approaches. Our hypothesis is that the inhibition produced by an original negative allosteric modulator will have the greatest effects on joint alterations and neuronal sensitization, along with the fewest side effects. This will open the field for an innovative anti-inflammatory pharmacological approach to early OA.